Recent developments in animal venom peptide nanotherapeutics with improved selectivity for cancer cells.

Abstract

Animal venoms are a rich source of bioactive peptides that efficiently modulate key receptors and ion channels involved in cellular excitability to rapidly neutralize their prey or predators. As such, they have been a wellspring of highly useful pharmacological tools for decades. Besides targeting ion channels, some venom peptides exhibit strong cytotoxic activity and preferentially affect cancer over healthy cells. This is unlikely to be driven by an evolutionary impetus, and differences in tumor cells and the tumor microenvironment are probably behind the serendipitous selectivity shown by some venom peptides. However, strategies such as bioconjugation and nanotechnologies are showing potential to improve their selectivity and potency, thereby paving the way to efficiently harness new anticancer mechanisms offered by venom peptides. This review aims to highlight advances in nano- and chemotherapeutic tools and prospective anti-cancer drug leads derived from animal venom peptides.

• Authors: Julien Giribaldi, Jennifer J Smith, Christina I Schroeder
• Journal: Biotechnology advances (Biotechnol Adv) 2021 Sep-Oct Vol. 50 Pg. 107769 ISSN: 1873-1899 [Electronic] England
• PMID: 33989705 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Review)
• Copyright: Published by Elsevier Inc.

Chemical References

• Peptides
• Venoms

Topics

• Animals
• Neoplasms (drug therapy)
• Peptides
• Prospective Studies
• Venoms